Lucia Masarova, MD

home / authors / lucia-masarova-md

Lucia Masarova, MD, is an assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Articles

Masarova on the Latest Updates Across Myeloproliferative Neoplasms

Masarova on the Latest Updates Across Myeloproliferative Neoplasms

April 15th 2024

Lucia Masarova, MD, PhD, discusses some of the latest updates across myeloproliferative neoplasms.

EXCEED-ET Study Evaluates Ropeginterferon alfa-2b-njf in ET

EXCEED-ET Study Evaluates Ropeginterferon alfa-2b-njf in ET

November 2nd 2023

Lucia Masarova, MD, PhD, discusses the rationale of the EXCEED-ET study of ropeginterferon alfa-2b-njf for patients with essential thrombocytopenia.

Masarova Discusses Ruxolitinib for Polycythemia Vera After Hydroxyurea

Masarova Discusses Ruxolitinib for Polycythemia Vera After Hydroxyurea

July 25th 2023

Lucia Masarova, MD, PhD, discusses therapeutic options for patients with polycythemia vera who are refractory to hydroxyurea.

Management and Treatment of Essential Thrombocythemia

Management and Treatment of Essential Thrombocythemia

June 6th 2023

Lucia Masarova, MD, discusses available treatment options for patients with essential thrombocythemia.

BET Inhibitor CPI-0610 Shows Potential as Treatment in Myelofibrosis

BET Inhibitor CPI-0610 Shows Potential as Treatment in Myelofibrosis

February 24th 2021

Lucia Masarova, MD, discusses the efficacy of CPI-0610 in the phase 2 MANIFEST trial in patients with myelofibrosis.

Immune Checkpoint Approaches in AML and MDS: A Next Frontier?

Immune Checkpoint Approaches in AML and MDS: A Next Frontier?

March 7th 2017

The researchers discuss the rationale for checkpoint-based therapies including antibodies to PD-1/PD-L1 and CTLA-4, an overview of clinical experience with these agents, and future considerations and combinations of these agents.